Our findings suggested that IL-6 or IL-8 can be utilized as independent predictors of efficacy and complement tumor markers CEA, CA50, CA199, and CA724 in predicting the effectiveness of immunotherapy in AGC patients. This evidence concerns the gene CXCL8 and neoplasm.